EMEA-002536-PIP02-24 - paediatric investigation plan
Lebrikizumab
PIPHuman
Key facts
- Invented name
- Ebglyss
- Active Substance
- Lebrikizumab
- Therapeutic area
- Respiratory, thoracic and mediastinal disorders
- Decision number
- P/0212/2024
- PIP number
- EMEA-002536-PIP02-24
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of nasal polyposis
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Almirall S.A.
Tel. +34 932912958
E-mail: sonia.barange@almirall.com- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date